Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus SODIUM CHLORIDE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE versus SODIUM CHLORIDE IN PLASTIC CONTAINER.
MAGNESIUM SULFATE vs SODIUM CHLORIDE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Sodium chloride is the principal extracellular cation and anion, respectively, in the body. It maintains osmotic pressure, fluid balance, and acid-base balance. It is essential for nerve conduction and muscle contraction.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
Intravenous infusion; dose and rate depend on patient's fluid and electrolyte status; typical maintenance: 0.9% NaCl at 1-2 mL/kg/h.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateTerminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Terminal half-life is approximately 24-48 hours in healthy individuals, primarily reflecting renal sodium handling and total body sodium pool; significantly prolonged in renal impairment.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Renal: >95% unchanged via glomerular filtration and tubular reabsorption. Fecal/biliary: negligible.
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."